title: A single administration of methamphetamine to mice early in the light period decreases running wheel activity observed during the dark period.
abstract: Repeated intermittent administration of amphetamines acutely increases appetitive and consummatory aspects of motivated behaviors as well as general activity and exploratory behavior, including voluntary running wheel activity. Subsequently, if the drug is withdrawn, the frequency of these behaviors decreases, which is thought to be indicative of dysphoric symptoms associated with amphetamine withdrawal. Such decreases may be observed after chronic treatment or even after single drug administrations. In the present study, the effect of acute methamphetamine (METH) on running wheel activity, horizontal locomotion, appetitive behavior (food access), and consummatory behavior (food and water intake) was investigated in mice. A multi-configuration behavior apparatus designed to monitor the five behaviors was developed, where combined measures were recorded simultaneously. In the first experiment, naïve male ICR mice showed gradually increasing running wheel activity over three consecutive days after exposure to a running wheel, while mice without a running wheel showed gradually decreasing horizontal locomotion, consistent with running wheel activity being a positively motivated form of natural motor activity. In experiment 2, increased horizontal locomotion and food access, and decreased food intake, were observed for the initial 3h after acute METH challenge. Subsequently, during the dark phase period decreased running wheel activity and horizontal locomotion were observed. The reductions in running wheel activity and horizontal locomotion may be indicative of reduced dopaminergic function, although it remains to be seen if these changes may be more pronounced after more prolonged METH treatments.
authors.affiliation: Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan.
authors.forename: Nobue
authors.initials: N
authors.lastname: Kitanaka
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitanaka
authors.forename: F Scott
authors.initials: FS
authors.lastname: Hall
authors.forename: George R
authors.initials: GR
authors.lastname: Uhl
authors.forename: Kaname
authors.initials: K
authors.lastname: Watabe
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kubo
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Tatsuta
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Morita
authors.forename: Motohiko
authors.initials: M
authors.lastname: Takemura
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002940:Circadian Rhythm / Q000187:drug effects*; D003624:Darkness; D008027:Light; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D051379:Mice; D008813:Mice, Inbred ICR; D009043:Motor Activity / Q000187:drug effects*
chemical_list: D000697:Central Nervous System Stimulants; D008694:Methamphetamine
references.citation: Pharmacol Biochem Behav. 1987 Apr;26(4):821-7
references.pmid: 2440058
references.citation: Neuropsychopharmacology. 2004 Feb;29(2):249-58
references.pmid: 12942147
references.citation: Psychopharmacology (Berl). 1991;103(4):480-92
references.pmid: 2062986
references.citation: J Pharm Pharmacol. 1978 Dec;30(12):798-9
references.pmid: 32250
references.citation: Psychopharmacologia. 1971;21(1):74-81
references.pmid: 5105870
references.citation: Behav Processes. 2005 Feb 28;68(2):165-72
references.pmid: 15686826
references.citation: Behav Brain Res. 2005 Nov 30;165(1):26-35
references.pmid: 16157394
references.citation: Behav Pharmacol. 1993;4(4):339-349
references.pmid: 11224202
references.citation: J Exp Anal Behav. 1993 Jul;60(1):219-38
references.pmid: 8354968
references.citation: Behav Brain Res. 2010 Dec 25;214(2):216-24
references.pmid: 20580749
references.citation: Annu Rev Psychol. 2003;54:25-53
references.pmid: 12185211
references.citation: Brain Res Brain Res Rev. 1997 Oct;25(2):192-216
references.pmid: 9403138
references.citation: Physiol Behav. 2006 Feb 28;87(2):368-76
references.pmid: 16364380
references.citation: Pharmacol Biochem Behav. 1994 Sep;49(1):41-6
references.pmid: 7816888
references.citation: Brain Res. 1986 Jun;396(2):157-98
references.pmid: 3527341
references.citation: Psychoneuroendocrinology. 2010 Feb;35(2):197-208
references.pmid: 19589643
references.citation: JAMA. 1967 Jul 31;201(5):305-9
references.pmid: 6071725
references.citation: Biol Psychiatry. 2001 Jul 15;50(2):137-43
references.pmid: 11526995
references.citation: Psychopharmacology (Berl). 2000 Aug;151(2-3):219-25
references.pmid: 10972468
references.citation: Res Commun Chem Pathol Pharmacol. 1978 Nov;22(2):313-28
references.pmid: 569889
references.citation: Neuropsychopharmacology. 2011 Jan;36(1):207-26
references.pmid: 20881946
references.citation: Eur J Pharmacol. 1983 Mar 25;88(2-3):195-203
references.pmid: 6133769
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1994 Mar;18(2):397-407
references.pmid: 8208988
references.citation: Eur J Pharmacol. 2003 Aug 1;474(1):63-70
references.pmid: 12909196
references.citation: Neurochem Res. 2008 Jan;33(1):204-19
references.pmid: 17605106
references.citation: Ann N Y Acad Sci. 2004 Oct;1025:279-87
references.pmid: 15542728
references.citation: Psychopharmacology (Berl). 1999 Feb;142(2):200-8
references.pmid: 10102773
references.citation: Behav Brain Res. 2009 Jul 19;201(1):74-9
references.pmid: 19428619
references.citation: Science. 1997 Oct 3;278(5335):52-8
references.pmid: 9311926
references.citation: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references.pmid: 8401595
references.citation: Behav Pharmacol. 2010 Jul;21(4):359-68
references.pmid: 20571366
references.citation: Eur Psychiatry. 2006 Dec;21(8):580-8
references.pmid: 17161285
references.citation: Pharmacol Biochem Behav. 1999 Nov;64(3):597-604
references.pmid: 10548277